Roche’s Ale­cen­sa trumps Pfiz­er’s Xalko­ri in front­line ALK+ lung can­cer

A lit­tle more than a year af­ter Roche won an ac­cel­er­at­ed ap­proval for Ale­cen­sa as a new drug for treat­ment-re­sis­tant ALK-pos­i­tive non-small cell lung can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER